Heart failure drug classes and 30-day unplanned hospital readmission among patients with heart failure in Ethiopia

被引:0
作者
Birhanu Ayenew
Prem Kumar
Adem Hussein
Yegoraw Gashaw
Mitaw Girma
Abdulmelik Ayalew
Beza Tadesse
机构
[1] Assosa University,Department of Adult Health Nursing, College of Health Science
[2] Wollo University,Department of Adult Health Nursing, College of Medicine and Health Science
[3] Assosa University,Department of Pediatric and Child Health Nursing, College of Health Science
[4] Wollo University,Department of Comprehensive Health Nursing, College of Medicine & Health Sciences
来源
Journal of Pharmaceutical Health Care and Sciences | / 9卷
关键词
Hospital readmission; Heart failure; Drug therapy; Ethiopia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 142 条
[1]  
Ziaeian B(2016)Epidemiology and aetiology of Heart Failure Nat Reviews Cardiol 13 368-78
[2]  
Fonarow GC(2016)Modeling future Cardiovascular Disease mortality in the United States: national trends and racial and ethnic disparities Circulation 133 967-78
[3]  
Pearson-Stuttard J(2016)Medical resource use and expenditure in patients with chronic Heart Failure: a population‐based analysis of 88 195 patients Eur J Heart Fail 18 1132-40
[4]  
Guzman-Castillo M(2022)Effectiveness of telemedicine visits in reducing 30-day readmissions among patients with Heart Failure during the COVID‐19 pandemic J Am Heart Association 11 e023935-23
[5]  
Penalvo JL(2020)Acute Heart Failure Nat Reviews Disease Primers 6 16-87
[6]  
Rehm CD(2018)A review of the role of the pharmacist in Heart Failure transition of care Adv Therapy 35 311-70
[7]  
Afshin A(2019)Updates in Heart Failure 30-day readmission prevention Heart Fail Rev 24 177-62
[8]  
Danaei G(2023)All-cause unplanned readmissions in the United States: insights from the Nationwide Readmission Database Intern Med J 53 262-97
[9]  
Farré N(2020)Management of Heart Failure and type 2 Diabetes Mellitus: maximizing complementary drug therapy Diabetes Obes Metabolism 22 1243-27
[10]  
Vela E(2019)Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors for the treatment of arterial Hypertension and the role of olmesartan Adv Therapy 36 278-44